Tropé-Kolstad Meeting 2014
Total Page:16
File Type:pdf, Size:1020Kb
5th Tropé - Kolstad meeting UPDATES IN GYNECOLOGIC ONCOLOGY Friday December 5, 2014 - 09:00 - 18:00 5th Tropé-‐Kolstad meeting Updates in Gynecologic Oncology Friday December 5, 2014 – Oslo 09:00 – 18:00 Sponsored by Inger and John Fredriksen Foundation for Ovarian Cancer Research The meeting takes place in the Auditorium of Building , K Institute for Cancer Research Oslo University Hospital, the Norwegian Radium Hospital SponsoredOslo, Norway by INGER AND JOHN FREDRIKSEN FOUNDATION FOR OVARIAN CANCER RESEARCH The meeting takes place in the Auditorium of Building K, Institute for Cancer Research Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway SCIENTIFIC PROGRAM DECEMBER 5 , 2014 09:00 – 09:05 Welcome Dr. Erik Rokkones, MD, PhD, Chairman of the Department of Gynaecological Oncology, the Norwegian Radium Hospital (Norway) Molecular Characteristics of Ovarian Cancer Chair: Dr. Anne Dørum, MD, PhD (Norway) 09:05 – 09:35 Chemoresistance Markers in Metastatic Ovarian Carcinoma Prof. Ben Davidson, MD, PhD (Norway) 09:35 – 09:40 Discussion 09:40 – 10:10 Molecular Predictor of Residuals in Patients with Ovarian Cancer Professor Beth Karlan, MD (USA) 10:10 – 10:15 Discussion 10:15 – 10:45 Impact of Oophorectomy on Cancer Incidence and Mortality in Women with BRCA1 or BRCA2 Mutation Prof. Pål Møller, MD, PhD Norway ( ) 10:45 – 10:50 Discussion 10:50 – 11:20 Coffee break 11:20 – 11:50 Does Overlap in Molecular and Histologic Subtypes Support New Strategies for Clinical Trials? Prof. Helga Salvesen, MD, PhD (Norway) 11:50 – 12:00 Discussion The 5th Tropé -‐Kolstad Lecture Introduction: Dr. M Bilal Sert, MD (Norway) 12:00 – 13:00 Epithelial Ovarian Cancer: A Real Challenge for the Next 25 Years! The Surgeon’s Viewpoints Prof. Neville Hacker, MD (Australia) 13:00 – 14:00 Lunch Controversies in Ovarian Cancer Treatment Chair: Dr. Tone Skeie-‐Jensen, MD, PhD (Norway) 14:00 – 14:40 Neoadjuvant Chemotherapy in Ovarian Cancer Pro: rofessor P Beth Karlan, MD (USA) Con: Prof. Neville Hacker, MD (Australia) 14:40 – 14:45 Discussion 14:45 – 15:05 Fluorescent Lymphatic ng Mappi in Gynecology Prof. Nadeem Abu-‐Rustum, MD (USA) 15:05 – 15:20 Secondary Cytoreduction of Recurrent Ovarian Cancer using Robotic Platform Dr. Ane Gerda Zahl Eriksson, MD (USA) 15:20 – 15:25 Discussion Ovarian Cancer and Pregnancy Chair: Dr. Janne Kærn, MD, PhD (Norway) 15:25 – 15:45 Ovarian Cancer in Pregnancy Prof. Frédéric Amant, MD, PhD (Belgium) 15:45 – 15:50 Discussion Germinal Cell Tumors of the Ovary Chair: Prof. Vera Abeler, MD, PhD (Norway) 15:50 – 16:10 Post-‐Treatment Fertility and Gonadal ction Fun in Young Women Diagnosed with a Malignant Ovarian Germ Cell Tumor (MOGCT) During the “Cisplatin Era” Dr. Olesya Solheim, MD (Norway) 16:10 – 16:15 Discussion Prospective Clinical Studies in Advanced Ovarian Cancer Chair: Prof. Bjørn Hagen, MD, PhD (Norway), Dr. Brynhildur Eyjólfsdóttir (Norway) 16:15 – 16:45 Updates of the Prospective Randomized Studies in Advanced Epithelial Ovarian Cancer in the World Today Professor Gunnar B Kristensen, MD, PhD ( Norway) 16:45 – 16:55 Discussion 16:55 – 17:25 Coffee break 17:25 – 17:45 Summary of the 2014 MD Andersson International Meeting in Ovarian Cancer: Emerging Therapies in Ovarian Cancer Prof. Nadeem Abu-‐Rustum, MD (USA) 17:45 – 17:55 Discussion 17:55 – 18:00 Closing remarks Professor Beth Karlan, MD (USA) Professor Ben Davidson, MD, PhD Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway Date and place of birth: September 23, 1964; Tel Aviv, Israel. Citizenship: Israeli Present position: Senior Pathologist and Head of Research, Department of Pathology, Oslo University Hospital; Professor, University of Oslo Education 2003-2004: Post-doctoral fellow at NCI/NIH, Bethesda MD 1998-2001: Ph.D. program, Norwegian Radium Hospital; Thesis defended 23/8/01 1986-1992: Medical studies in Sackler School of Medicine, Tel-Aviv University Brief Chronology of employment 2002-present: Staff pathologist, Department of Pathology, Norwegian Radium Hospital, Oslo, Norway; Sub-specialist in cytopathology and gynecologic pathology 1998-2002: Resident (combined with PhD program), Department of Pathology, Norwegian Radium Hospital, Oslo, Norway 1994-1998: Resident, Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel Membership in professional and scientific societies 1. The American Association for Cancer Research; 2. The International Academy of Pathology (Norwegian division); 3. The European Society of Pathology; 4. The International Society of Gynecological Pathology; 5. Nordic Society of Gynecologic Oncology Scientific appointments 2012-: Editorial board member in Gynecologic Oncology 2011-: Associate Editor, Frontiers in Women’s Cancer 2011-: Editorial board member in Human Pathology 2010-: Editorial board member in Virchows Archiv 2010: Associate Editor, Journal of Oncology, Special issue titled Molecular Genetic Markers in Female Reproductive Cancers 2006-2013: Member of the grant application committee, Norwegian Cancer Society 2005-2012: Section Editor in Diagnostic Cytopathology Invited speaker and Reviewer - Reviewed a large number of manuscripts for leading international peer-reviewed journals, including Nature Reviews Cancer, Lancet Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Annals of Oncology, The American Journal of Pathology, Oncogene and Cancer. - Invited speaker in 26 sessions in international conferences in 2004-2014 Publications (excluding abstracts) in peer-reviewed journals: 257 per November 2014 In addition, Editor of a book on serous effusions with Springer and author of 5 chapters. Professor Pål Møller, MD, PhD Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway MD, PhD, Senior Consultant, Senior Scientist. From a background of internal medicine and a PhD on multifactorial inheritance, he was in 1988 asked to erect combined research on and health service for inherited cancer at the Norwegian Radium Hospital – currently a unit within Oslo University Hospital. He joined the international organizations developing the mathematical models to describe inherited cancer, and the inter-professional organizations describing the inherited cancer syndromes, uncover their genetic causes and advocating intervention strategies to prevent and cure. Genetic understanding is based upon genetic epidemiological facts on the inherited diseases in question, to which purpose he together with the organizations mentioned issued standardized guidelines for health care. Implementing these in the Norwegian health care system which covers all Norwegian, the system was made an open observational trial. Together with others having the same intention on providing information based on prospective observations (not only retrospective as close to all information was and still is), he became partner in broad international collaborative prospective studies. To this end he had to keep all relevant information, and in the absence of systems to do so he made his own combined electronic medical filing and research system. Today, information from the thousands of families examined the last 25 years, including results of testing for the known causative genes and effects of interventions over all these years, are available to describe the genetic epidemiology of the inherited cancers and the effects of the interventions undertaken. Because of numbers needed to arrive at conclusions, it is necessary to compile international series from different centres, for which reason the broad international collaborations are continuously ongoing. Inherited ovarian cancer is part of inherited breast-ovarian cancer caused by the BRCA1/2 genes and inherited colorectal cancer (Lynch syndrome) caused by four mismatch-repair genes. Updates from the international collaborative prospective studies on these two inherited cancers syndromes will be given. Professor Beth Y. Karlan, MD Cedars-Sinai Medical Center, Los Angeles, CA, USA Position title Director, Women’s Cancer Program. Director, Gynecologic Oncology Education/training: Institution and location, degree, year(s), field of study Harvard-Radcliffe College, Cambridge, MA , B.A., 1978, Biochemistry Sciences Harvard Medical School, Cambridge, MA, M.D., 1982, Medicine Yale-New Haven Hospital, New Haven, CT, Residency, 1982-86, Obstetrics & Gynecology Yale Univ. School of Medicine, New Haven, CT, Research Fellow, 1986-87, Molecular Biology UCLA School of Medicine, Los Angeles, CA, Clinical Fellow, 1987-89, Gynecologic Oncology Personal statement As a physician and translational researcher, I have more than 30 years experience treating patients with female reproductive malignancies and investigating pressing clinical questions in the clinic and the laboratory. My research interests include the genetic and phenotypic determinants of human ovarian carcinoma, hereditary predisposition to cancer, and molecular biomarkers for early detection, treatment and prognostication of ovarian cancer. I have been awarded research grants from the Department of Defense, National Institutes of Health and the American Cancer Society. In 1989 I established a human tissue biorepository to collect and preserve fresh frozen tissue, serum, germline DNA from blood and paraffin blocks to be used for translational research studies. As of 2013, the collection contains more than 100,000 unique specimens donated by more than 10,000 patients and correlated with relevant clinical data. This robust and valuable resource has been the backbone of much of